IP Library › Granted Patent US 12,195,447
Granted Patent B2
US 12,195,447 · App. 17/507,921 · Granted Jan 14, 2025

Azolopyrimidine for the treatment of cancer-related disorders

Inventors: Joel Beatty (San Mateo, CA); Laurent Debien (San Francisco, CA); Jenna Jeffrey (Oakland, CA); Manmohan Reddy Leleti (Dublin, CA); Debashis Mandal (Fremont, CA); Dillon Miles (Berkeley, CA); Jay Powers (Pacifica, CA); Brandon Rosen (San Mateo, CA); Ehesan Sharif (Menlo Park, CA); Rhiannon Thomas-Tran (San Jose, CA)
Assignee: ARCUS BIOSCIENCES, INC.
C07D401/14A61K31/506A61K31/5377A61K45/06C07D403/04C07D403/14C07D405/14C07D413/14C07D417/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,195,447
App. No.
17/507,921
Granted
Jan 14, 2025
Kind
B2
Abstract

Compound that is an inhibitor of at least one of the A 2A and A 2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A 2A receptor and/or the adenosine A 2B receptor.

Claims (3)

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2022
From: BEATTY, JOEL; DEBIEN, LAURENT; JEFFREY, JENNA; LELETI, MANMOHAN REDDY; MANDAL, DEBASHIS; MILES, DILLON; POWERS, JAY; ROSEN, BRANDON; SHARIF, EHESAN; THOMAS-TRAN, RHIANNON
To: ARCUS BIOSCIENCES, INC.
Reel/Frame 058813/0233 →
Continuity (6)
Continuation 17346918 · Jun 14, 2021
Continuation 16460263 · Jul 2, 2019
Continuation 15875106 · Jan 19, 2018
Provisional Application 62479005 · Mar 30, 2017
Provisional Application 62448608 · Jan 20, 2017
Related Publication 20220144808A1 · May 12, 2022
References Cited (46)
US 10399962B2 · Beatty et al. · 2019 [cited by applicant]
US 11072597B2 · Beatty et al. · 2021 [cited by applicant]
US 20110275611A1 · Axten et al. · 2011 [cited by applicant]
US 20130289017A1 · Dorsch et al. · 2013 [cited by applicant]
US 20150018351A1 · Lind et al. · 2015 [cited by applicant]
EP 1439175A1 · 2004 [cited by applicant]
WO 2005058883A2 · 2005 [cited by applicant]
WO 2008005457A2 · 2008 [cited by applicant]
WO 2009156737A1 · 2009 [cited by applicant]
WO 2010059658A1 · 2010 [cited by applicant]
WO 2012095142A1 · 2012 [cited by applicant]
WO WO2015085909 · 2015 [cited by applicant]
WO WO2017088755 · 2017 [cited by applicant]
WO 2018136700A1 · 2018 [cited by applicant]
WO 2018152450A1 · 2018 [cited by applicant]
WO 2018182051A1 · 2018 [cited by applicant]
WO 2018183418A1 · 2018 [cited by applicant]
WO 2018183964A1 · 2018 [cited by applicant]
Sangaraiah Nagarajan et al. An eco-friendly water mediated synthesis of 1,2,3-triazolyl-2-aminopyrimidine hybrids as highly potent anti-bacterial agents. Chinese Chemical Letters 25 (2014) 419-422 (Year: 2014). [cited by examiner]
International Search Report and Written Opinion mailed Mar. 8, 2018 corresponding to PCT/US2018/014352 filed Jan. 19, 2018; 11 pages. [cited by applicant]
Extended European Search Report for EP Application No. 18741044.4 mailed May 13, 2020, 9 pages. [cited by applicant]
Davari et al., “Synthesis and biological evaluation of novel pyridine derivatives as potential anticancer agents and phosphodiesteras-3 inhibitors”, Bioorganic Chemistry, Dec. 1, 2014, vol. 57, pp. 83-89. [cited by applicant]
Mitsos “Isoters in Medicinal Chemistry”, 2006, https://www.scripps.edu/baran/images/grpmtgpdf/Mitsos_Group Meeting Feb. 1, 2006.pdf; 7 pages. [cited by applicant]
Murugavel et al., “Synthesis, Crystal /structure aand DFT Studies of 4-(1-Benzyl-5-mthyl-1H-1,2,3-triazol-4-yl)-6-(o-tolyl)pyrimidin-2-amine”, Database CAPLUS, Database accession No. 2015:631662, abstract. [cited by applicant]
Nagarajan et al., “An eco-friendly water mediated synthesis of 1,2,3-triazolyl-2-aminopyrimidine hybrids as highly potent anti-bacterial agents”, Chinese Chemical Letter, 2014, vol. 25, pp. 419-422. [cited by applicant]
Examination Report for Australian Application No. 2022203515 dated Feb. 14, 2023. 3 pages. [cited by applicant]
Examination Report for New Zealand Application No. 754731 dated Feb. 24, 2022. 4 pages. [cited by applicant]
Examination Report for New Zealand Application No. 754731 dated Sep. 9, 2022. 2 pages. [cited by applicant]
Murugavel, S. et al., “Synthesis, Crystal Structure and DFT Studies of 4-(1-Benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-6-(o-tolyl)pyrimidin-2-amine”, Asian Journal Of Chemistry 2015, 27(3), 974-978. [cited by applicant]
Murugavel, S. et al., Crystal structure and DFT studies of 4-(1-benzyl-5-methyl-1H-1,2,3-triazol-4yl)-6-phenylpyrimidin-2-amine, Indian Journal of Pure & Applied Physics 2016, vol. 54, pp. 199-208. [cited by applicant]
Notice of Preliminary Rejection for Korean Application No. 10-2019-7024140 dated Apr. 12, 2023. 6 pages. [cited by applicant]
Office Action and Search Report for Taiwan Application No. 107101999 dated Dec. 6, 2021. 8 pages. [cited by applicant]
Office Action for Argentina Application No. 20180100131 dated Feb. 2, 2022. 4 pages. [cited by applicant]
Office Action for Brazilian Application No. BR112019014193-6 dated Aug. 17, 2022. 5 pages. [cited by applicant]
Office Action for Chinese Application No. 201880007563.X dated Apr. 26, 2022. 19 pages. [cited by applicant]
Office Action for Chinese Application No. 201880007563.X dated Oct. 18, 2022. 7 pages. [cited by applicant]
Office Action for Vietnam Application No. 1-2019-04437 for Jan. 28, 2022. 3 pages. [cited by applicant]
Official Action for Japanese Application No. 2022-15648 dated Mar. 23, 2023. 3 pages. [cited by applicant]
Yang et al., Identification of a New Series of Potent Adenosine A2A Receptor Antagonists Based on 4-Amino-5-carbonitrile Pyrimidine Template for the Treatment of Parkinson's Disease, ACS Chemical Neuroscience 2016, 7(11… [cited by applicant]
Examination Report and Search Report for United Arab Emirates Application No. P6001023/2019 dated Oct. 23, 2023. 11 pages. [cited by applicant]
Examination Report for Malaysian Application No. PI2019003049 dated Oct. 30, 2023. 3 pages. [cited by applicant]
Official Action for Japanese Application No. 2022-15648 dated Nov. 6, 2023. 5 pages. [cited by applicant]
Examination Report for Qatar Application No. QA/201907-00373 dated Jan. 31, 2024. 2 pages. [cited by applicant]
Examiner's Report for Canadian Application No. 3,047,600 dated Dec. 18, 2023. 7 pages. [cited by applicant]
Extended European Search Report for European Application No. 23194932.2 dated Mar. 11, 2024. 9 pages. [cited by applicant]
Official Action for Uruguay Application No. 37.574 dated Mar. 5, 2024. 11 pages. [cited by applicant]
Cited By (2)
US 12,453,738 US 12,630,526